High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL

Blinatumomab is a bispecific T-cell engager approved for B-cell precursor acute lymphoblastic leukemia (B-ALL) with persistent minimal residual disease (MRD) or in relapse. The prognostic impact of tumor load has been suggested before other immunotherapies but remains poorly explored before blinatu...

詳細記述

書誌詳細

主要な著者:	Aurelie Cabannes-Hamy, Eolia Brissot, Thibaut Leguay, Francoise Huguet, Patrice Chevallier, Mathilde Hunault, Martine Escoffre-Barbe, Thomas Cluzeau, Marie Balsat, Stephanie Nguyen, Florence Pasquier, Magda Alexis, Veronique Lheritier, Cedric Pastoret, Eric Delabesse, Emmanuelle Clappier, Herve Dombret, Nicolas Boissel
フォーマット:	Artigo
言語:	Inglês
出版事項:	Ferrata Storti Foundation 2022-03-01
シリーズ:	Haematologica
オンライン･アクセス:	https://haematologica.org/article/view/10569
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!